Bardoxolone FDA Approval Status
FDA Approved: No
Generic name: bardoxolone
Company: Reata Pharmaceuticals, Inc.
Treatment for: Alport Syndrome
Bardoxolone is an investigational, once-daily, orally administered activator of Nrf2 in development for the treatment of Alport syndrome and autosomal dominant polycystic kidney disease (ADPKD).
Development Timeline for bardoxolone
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.